Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06940739 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 4 to 5v4
  2. Study sites: 2 to 4 Secondary endpoints: 9 to 10v3 Show 1 more changeShow less
    • Secondary endpoints: 9 to 10

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 1 to 2v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Iovance Biotherapeutics
12 trials monitored
See 1 trial at risk
Melanoma
1,026 trials monitored
See 48 trials at risk
A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
Trial Details
NCT Number NCT06940739
Lead Sponsor Iovance Biotherapeutics, Inc.
Conditions Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov